<DOC>
	<DOC>NCT00868959</DOC>
	<brief_summary>This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression</brief_summary>
	<brief_title>Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject is judged by the investigator to be suitable for participation in a 24week clinical trial involving openlabel lurasidone treatment Subject has completed the 6week treatment period and all required assessments on the final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study D1050236, NCT#008668699. Imminent risk of suicide, injury to self or to others, or damage to property Subject has evidence of severe movement disorders. Subject tests positive for drugs of abuse (at Visit 8 in Study D1050235, NCT#00868452 or D1050236, NCT#008688699).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bipolar</keyword>
	<keyword>Depression</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>